NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Is the "compassionate" data in the 3/15/23 slides from: 1) UK Specials program, 2) UK Specials program , plus UCLA-LIAU combination trial cases , 3) the NWBO information arm (can't be this because the information arm patients have non GBM solid tumors , and they are getting DC VAX DIRECT)?



In slides 29 and 30 , are the big black open spaces now void of a GBM tumor that previously occupied that space ?

http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
flipper44


https://nwbio.com/dcvax-direct-phase-iii-for-all-types-of-inoperable-solid-tumor-cancers/

Member Level
Re: flipper44 post# 577183

Thursday, 03/16/2023 12:01:55 PM

Continued:

•DCVax-L is well tolerated and can be effective in older patients, at least through late 80s ages

•When patients experience recurrence, and have an additional resection, a new batch of DCVax-L can be made and patients can respond, with extended survival

•When patients experience recurrence before all doses are used, continuing treatment with the original DCVax-L batch can still extend survival



The first bullet point is previously unheard of.

The second bullet point is previously unheard of.

The third bullet point is previously unheard of.


DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
Our DCVax-Direct product offers a potential new treatment option for the wide range of clinical situations in which patients’ tumors are considered “inoperable” because the patient has multiple tumors, or their tumor cannot be completely removed, or the surgery would cause undue damage to the patient and impair their quality of life.

A large number of patients with a variety of cancer types (including lung, colon, pancreatic, liver, ovarian, head and neck, and others) are faced with this situation, because their tumors are already locally advanced or have begun to metastasize by the time symptoms develop and the patients seek treatment. For these patients, the outlook today is bleak and survival remains quite limited.

DCVax-Direct is administered by direct injection into a patient’s tumors. It can be injected into any number of tumors, enabling patients with locally advanced disease or with metastases to be treated. DCVax-Direct can also be injected into tumors in virtually any location in the body: not only tissues at or near the surface of the body but also, with ultra-sound guidance, into interior tissues.

We are currently conducting a 60-patient Phase I/II trial of DCVax-Direct for all types of inoperable solid tumors. The trial is under way at MD Anderson in Houston, TX and MD Anderson in Orlando, FL, with additional sites in varying stages of preparation. The eligibility criteria can be found in the profile of this trial on www.clinicaltrials.gov. The Phase I stage of the trial involves dose escalation, testing 3 different dose levels of DCVax-Direct, and confirmation of the optimal dose. The Phase II stage of the trial will focus on efficacy. The primary measure of efficacy will be regression (i.e., shrinkage or elimination) of the patient’s existing inoperable tumors. Such regression is a rapid endpoint: if it is going to occur, is anticipated to occur within a couple months of treatment.

If you do not meet the eligibility requirements for clinical trials, please contact us here.

Follow us On:
DCVAX® TECHNOLOGY
About DCVax®
Dendritic Cell Immunotherapy
Patient Stories & Physician Comments
PRODUCT CANDIDATES
DCVax® – L
DCVax® – Direct
DCVax® – Prostate
CLINICAL TRIALS
Pipeline
DCVax® – L Phase III
DCVax® – Direct Phase I/II


Michael Bigger
@biggercapital
·
1h
Mind Blown by Compassionate Cases Data. 10 yrs #GBM survivors a heck of a benefit to society. http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf $NWBO Safe with Benefits = APPROVAL


ae kusterer

Re: None

Thursday, March 16, 2023 3:35:02 PM

Post#
577335
of 577382
The compassionate use data in the 3/15/23 Bosch slides appears to be heading toward corroboration of Dr. Ashkan's 5/21/21 statement in the spotify link below (at the 26 minute mark) , " 1/3 of my patients are living 7-8 years."

Questions:
1) is the compassionate use data only from the U.K., or is UCLA-Liau Clinic data included?

2) Is a peer reviewed scientific publication in the works for the DC VAX L compassionate use data?

https://open.spotify.com/episode/68Dkypq2S27mN2e03wWFtw?si=ExI9kXfPS8SxUt5X01ayeQ&utm_source=copy-link

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171464546



577315

is the compassionate use data just from Ashkan's 200-300 GM patients he has treated in the U.K. Specials program?


alphavestcapital.com
@alphavestcap

http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf $nwbo
@alphavestcap
The compassionate use slides (3/15/23) are unblinding the 200-250 DC VAX L patients(NYAS - 5/10/22) in the U.K. Specials program. spotify 5/15/21, 25 min, Ashkan , " 1/3 of my patients are living 7-8 years."

@biggercapital
·
May 23, 2021
“At 26 mins Dr.Ashkan "my most interesting research project, an inmmune system vaccine. In the unblinded paper, a segmant of the patient population lived an unprecedented 7-8 years.Soon, we should have access to the unblinded data. We need a cure for the #GBM ."”$NWBO twitter.com/medspirepodcas…